261280558 Stock Overview
A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PharmaEssentia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$17.50 |
| 52 Week High | NT$0 |
| 52 Week Low | NT$0 |
| Beta | 0.51 |
| 11 Month Change | -13.37% |
| 3 Month Change | -19.72% |
| 1 Year Change | 54.35% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 26.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| 261280558 | LU Biotechs | LU Market | |
|---|---|---|---|
| 7D | -3.8% | 2.9% | -0.8% |
| 1Y | 54.3% | 5.3% | 0.6% |
Return vs Industry: 261280558 exceeded the Luxembourg Biotechs industry which returned 5.3% over the past year.
Return vs Market: 261280558 exceeded the Luxembourg Market which returned 0.1% over the past year.
Price Volatility
| 261280558 volatility | |
|---|---|
| 261280558 Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in LU Market | 6.4% |
| 10% least volatile stocks in LU Market | 3.1% |
Stable Share Price: 261280558 has not had significant price volatility in the past 3 months compared to the Luxembourg market.
Volatility Over Time: 261280558's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Ko-Chung Lin | www.pharmaessentia.com |
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
PharmaEssentia Corporation Fundamentals Summary
| 261280558 fundamental statistics | |
|---|---|
| Market cap | US$5.80b |
| Earnings (TTM) | US$56.66m |
| Revenue (TTM) | US$255.41m |
102.4x
P/E Ratio22.7x
P/S RatioIs 261280558 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 261280558 income statement (TTM) | |
|---|---|
| Revenue | NT$8.32b |
| Cost of Revenue | NT$1.07b |
| Gross Profit | NT$7.25b |
| Other Expenses | NT$5.40b |
| Earnings | NT$1.85b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.55 |
| Gross Margin | 87.10% |
| Net Profit Margin | 22.19% |
| Debt/Equity Ratio | 0.3% |
How did 261280558 perform over the long term?
See historical performance and comparison